Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Qurient Co., Ltd. (115180:KRX), powered by AI.
Qurient Co., Ltd. is currently trading at ₩39,400. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Qurient Co., Ltd. on Alpha Lenz.
Qurient Co., Ltd.'s P/E ratio is -52.4.
“Qurient Co., Ltd. trades at a P/E of -52.4 (undervalued) with modest ROE of -45.2%. 3Y revenue CAGR of 23.4% highlights clear growth momentum.”
Ask for details →Qurient Co., Ltd. is a biotechnology company primarily engaged in the development of innovative therapeutics targeting cancer and inflammatory diseases. The company focuses on advancing its proprietary pipeline of small molecule drugs through rigorous research and development. Qurient Co., Ltd. aims to address unmet medical needs by leveraging its expertise in immuno-oncology and NCE (new chemical entity) drug discovery platforms. The company's endeavors encompass the stages from preclinical studies through clinical trials, striving for breakthroughs that enhance patient care and outcomes. Operating within the dynamic biopharmaceutical sector, Qurient plays a critical role in the advancement of healthcare technology and therapeutics. Headquartered in South Korea, the company collaborates with academic institutions and industry partners globally to achieve its objectives. Qurient Co., Ltd. stands out in the healthcare market by contributing to the innovation of treatment options, thereby holding significance in reshaping therapeutic landscapes.
“Qurient Co., Ltd. trades at a P/E of -52.4 (undervalued) with modest ROE of -45.2%. 3Y revenue CAGR of 23.4% highlights clear growth momentum.”
Ask for details →Qurient Co., Ltd. (ticker: 115180) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 31 employees. Market cap is $1.5T.
The current price is ₩39,400 with a P/E ratio of -52.41x and P/B of 21.44x.
ROE is -45.23% and operating margin is -299.33%. Annual revenue is $9.2B.